For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Anticancer Agent Xtandi Receives Approval Also in Europe: Astellas
June 26, 2013
- Filgrastim Biosimilars: Overseas Track Record vs. “Purely Made-in-Japan” Label
June 25, 2013
- Novartis AG Probing 10-Plus Years of Documents, Emails over Diovan Papers
June 25, 2013
- Taiho to Launch New Formulation TS-1, World’s 1st Anticancer OD Tablets
June 25, 2013
- UMN, API, Yakult Officially Agree on Joint Biosimilar Business
June 24, 2013
- Toho Holdings Targets 26.1 Billion Yen Operating Profit in FY2015
June 24, 2013
- Volibris Receives Orphan Drug Designation for Indication of CTEPH in Japan: GSK
June 24, 2013
- Kowa, Sanofi File NDAs for SGLT-2 Inhibitor Tofogliflozin in Japan
June 24, 2013
- Kitasato Daiichi Sankyo Vaccine Submits NDA for Cell-Based Pandemic Flu Vaccine
June 24, 2013
- Industry FTC Finds Only 1 Violation of New Rules on Settai in FY2012 Following Their Introduction
June 21, 2013
- Anatomy of Mutual Reliance - Diovan Papers and Company Part 2: Explanations to the World Urged
June 21, 2013
- MSD Revives “US Training” Program to Enhance Skills of Outstanding MRs
June 21, 2013
- Baxter Receives Approval for Cell-Based H5N1 Vaccine
June 20, 2013
- Daiichi Sankyo Files NDA for Next Mainstay Product Prasugrel in Japan
June 20, 2013
- AZ, BMKK Aim to Develop Market for Bydureon as Drug before Insulin
June 20, 2013
- Anatomy of Mutual Reliance - Diovan Papers and Company Part 1: A Blurred Line
June 20, 2013
- Takeda’s 3 Nesina Family Drugs Make US Debut
June 19, 2013
- MSD to Continue Efforts for HPV Vaccine Recommendation
June 19, 2013
- Novartis Pharma to Voluntarily Refrain from Participation in JPMA’s Board of Directors Meeting
June 19, 2013
- Chairman Kato Resigns, to Move to Specially Appointed Professor Position at University of Tokyo: AZ
June 19, 2013
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…